AQST News and Press, Aquestive Therapeutics Inc. From 03/14/24

2024-03-14 18:32:04 ET DENVER, Colo., Mar 14, 2024 ( 247marketnews.com )- Aquestive Therapeutics, Inc. (NASDAQ: AQST ) released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm (epinephrine), the Company’s first and only ...

Anaphylm meets all predefined primary and secondary pharmacokinetic endpoints Anaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectors Anaphylm exposure levels (AUC) are comparable to autoinjectors for 30 minutes after dosing Anaphylm is we...

2024-03-06 10:11:05 ET Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Conference Call March 06, 2024, 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Offic...

2024-03-06 00:58:49 ET More on Aquestive Therapeutics Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1 Seeking Alpha’s Quant Rating on Aquestive Therapeutics Historical earnings data for Aquestive Therapeutics Financia...

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million Reaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024 Reaffirms anticipated FDA decision on Libervant™ (diazep...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection. Anaphylm candidate, with the potential to be the first and only no...

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will particip...

2024-01-19 17:05:19 ET Summary Aquestive Therapeutics is nearing a key topline readout for its Anaphylm sublingual film, a potential groundbreaking oral epinephrine treatment for severe allergic reactions. If the data is positive, Anaphylm could be heading for a possible New Drug ...